Research ArticleEndocrine and Diabetes
Analysis of the Effect of Canagliflozin on Renal Glucose Reabsorption and Progression of Hyperglycemia in Zucker Diabetic Fatty Rats
Chiaki Kuriyama, Jun Zhi Xu, Seunghun Paul Lee, Jenson Qi, Hirotaka Kimata, Tetsuhiro Kakimoto, Keiko Nakayama, Yoshinori Watanabe, Nobuhiko Taniuchi, Kumiko Hikida, Yasuaki Matsushita, Kenji Arakawa, Akira Saito, Kiichiro Ueta and Masaharu Shiotani
Journal of Pharmacology and Experimental Therapeutics November 2014, 351 (2) 423-431; DOI: https://doi.org/10.1124/jpet.114.217992
Chiaki Kuriyama
Research Division, Mitsubishi Tanabe Pharma Corporation, Toda-shi, Saitama, Japan (C.K., H.K., T.K., K.N., Y.W., N.T., K.H., Y.M., K.A., A.S., K.U., M.S.); and Janssen Research & Development LLC, Spring House, Pennsylvania (J.Z.X., S.P.L., J.Q.)
Jun Zhi Xu
Research Division, Mitsubishi Tanabe Pharma Corporation, Toda-shi, Saitama, Japan (C.K., H.K., T.K., K.N., Y.W., N.T., K.H., Y.M., K.A., A.S., K.U., M.S.); and Janssen Research & Development LLC, Spring House, Pennsylvania (J.Z.X., S.P.L., J.Q.)
Seunghun Paul Lee
Research Division, Mitsubishi Tanabe Pharma Corporation, Toda-shi, Saitama, Japan (C.K., H.K., T.K., K.N., Y.W., N.T., K.H., Y.M., K.A., A.S., K.U., M.S.); and Janssen Research & Development LLC, Spring House, Pennsylvania (J.Z.X., S.P.L., J.Q.)
Jenson Qi
Research Division, Mitsubishi Tanabe Pharma Corporation, Toda-shi, Saitama, Japan (C.K., H.K., T.K., K.N., Y.W., N.T., K.H., Y.M., K.A., A.S., K.U., M.S.); and Janssen Research & Development LLC, Spring House, Pennsylvania (J.Z.X., S.P.L., J.Q.)
Hirotaka Kimata
Research Division, Mitsubishi Tanabe Pharma Corporation, Toda-shi, Saitama, Japan (C.K., H.K., T.K., K.N., Y.W., N.T., K.H., Y.M., K.A., A.S., K.U., M.S.); and Janssen Research & Development LLC, Spring House, Pennsylvania (J.Z.X., S.P.L., J.Q.)
Tetsuhiro Kakimoto
Research Division, Mitsubishi Tanabe Pharma Corporation, Toda-shi, Saitama, Japan (C.K., H.K., T.K., K.N., Y.W., N.T., K.H., Y.M., K.A., A.S., K.U., M.S.); and Janssen Research & Development LLC, Spring House, Pennsylvania (J.Z.X., S.P.L., J.Q.)
Keiko Nakayama
Research Division, Mitsubishi Tanabe Pharma Corporation, Toda-shi, Saitama, Japan (C.K., H.K., T.K., K.N., Y.W., N.T., K.H., Y.M., K.A., A.S., K.U., M.S.); and Janssen Research & Development LLC, Spring House, Pennsylvania (J.Z.X., S.P.L., J.Q.)
Yoshinori Watanabe
Research Division, Mitsubishi Tanabe Pharma Corporation, Toda-shi, Saitama, Japan (C.K., H.K., T.K., K.N., Y.W., N.T., K.H., Y.M., K.A., A.S., K.U., M.S.); and Janssen Research & Development LLC, Spring House, Pennsylvania (J.Z.X., S.P.L., J.Q.)
Nobuhiko Taniuchi
Research Division, Mitsubishi Tanabe Pharma Corporation, Toda-shi, Saitama, Japan (C.K., H.K., T.K., K.N., Y.W., N.T., K.H., Y.M., K.A., A.S., K.U., M.S.); and Janssen Research & Development LLC, Spring House, Pennsylvania (J.Z.X., S.P.L., J.Q.)
Kumiko Hikida
Research Division, Mitsubishi Tanabe Pharma Corporation, Toda-shi, Saitama, Japan (C.K., H.K., T.K., K.N., Y.W., N.T., K.H., Y.M., K.A., A.S., K.U., M.S.); and Janssen Research & Development LLC, Spring House, Pennsylvania (J.Z.X., S.P.L., J.Q.)
Yasuaki Matsushita
Research Division, Mitsubishi Tanabe Pharma Corporation, Toda-shi, Saitama, Japan (C.K., H.K., T.K., K.N., Y.W., N.T., K.H., Y.M., K.A., A.S., K.U., M.S.); and Janssen Research & Development LLC, Spring House, Pennsylvania (J.Z.X., S.P.L., J.Q.)
Kenji Arakawa
Research Division, Mitsubishi Tanabe Pharma Corporation, Toda-shi, Saitama, Japan (C.K., H.K., T.K., K.N., Y.W., N.T., K.H., Y.M., K.A., A.S., K.U., M.S.); and Janssen Research & Development LLC, Spring House, Pennsylvania (J.Z.X., S.P.L., J.Q.)
Akira Saito
Research Division, Mitsubishi Tanabe Pharma Corporation, Toda-shi, Saitama, Japan (C.K., H.K., T.K., K.N., Y.W., N.T., K.H., Y.M., K.A., A.S., K.U., M.S.); and Janssen Research & Development LLC, Spring House, Pennsylvania (J.Z.X., S.P.L., J.Q.)
Kiichiro Ueta
Research Division, Mitsubishi Tanabe Pharma Corporation, Toda-shi, Saitama, Japan (C.K., H.K., T.K., K.N., Y.W., N.T., K.H., Y.M., K.A., A.S., K.U., M.S.); and Janssen Research & Development LLC, Spring House, Pennsylvania (J.Z.X., S.P.L., J.Q.)
Masaharu Shiotani
Research Division, Mitsubishi Tanabe Pharma Corporation, Toda-shi, Saitama, Japan (C.K., H.K., T.K., K.N., Y.W., N.T., K.H., Y.M., K.A., A.S., K.U., M.S.); and Janssen Research & Development LLC, Spring House, Pennsylvania (J.Z.X., S.P.L., J.Q.)
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
In this issue
Research ArticleEndocrine and Diabetes
Canagliflozin Improves Hyperglycemia in ZDF Rats
Chiaki Kuriyama, Jun Zhi Xu, Seunghun Paul Lee, Jenson Qi, Hirotaka Kimata, Tetsuhiro Kakimoto, Keiko Nakayama, Yoshinori Watanabe, Nobuhiko Taniuchi, Kumiko Hikida, Yasuaki Matsushita, Kenji Arakawa, Akira Saito, Kiichiro Ueta and Masaharu Shiotani
Journal of Pharmacology and Experimental Therapeutics November 1, 2014, 351 (2) 423-431; DOI: https://doi.org/10.1124/jpet.114.217992
Research ArticleEndocrine and Diabetes
Canagliflozin Improves Hyperglycemia in ZDF Rats
Chiaki Kuriyama, Jun Zhi Xu, Seunghun Paul Lee, Jenson Qi, Hirotaka Kimata, Tetsuhiro Kakimoto, Keiko Nakayama, Yoshinori Watanabe, Nobuhiko Taniuchi, Kumiko Hikida, Yasuaki Matsushita, Kenji Arakawa, Akira Saito, Kiichiro Ueta and Masaharu Shiotani
Journal of Pharmacology and Experimental Therapeutics November 1, 2014, 351 (2) 423-431; DOI: https://doi.org/10.1124/jpet.114.217992
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement